We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · August 21, 2020

Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of DKD Categories

Diabetes, Obesity & Metabolism

 

Additional Info

Diabetes, Obesity & Metabolism
Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories — Insights From the EMPA-REG OUTCOME Trial
Diabetes Obes Metab 2020 Aug 03;[EPub Ahead of Print], C Wanner, SE Inzucchi, B Zinman, A Koitka-Weber, MMD Biomath, JT George, M von Eynatten, SJ Hauske

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading